Do Wall Street Analysts Like Edwards Lifesciences Stock?

With a market cap of $44.3 billion, Edwards Lifesciences Corporation (EW) provides products and technologies to treat advanced cardiovascular diseases internationally. The company’s product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. 

Shares of Edwards Lifesciences have lagged behind the broader market over the past 52 weeks. EW has dropped 10.9% over this time frame, while the broader S&P 500 Index ($SPX) has gained 12.7%. However, shares of EW are up 2% on a YTD basis, outpacing SPX’s marginal return during the same time frame.